AML in mice transplanted with oncogene‐transduced Tgif1−/− HSPCs shows an impaired response to conventional chemotherapy agents used to treat myeloid malignancy and correlates with earlier relapse and shorter survival compared to similarly transduced Tgif1+/+ controls. The gene discussed is TGIF1; the disease is acute myeloid leukemia.